Malignant lymphoma - survey of recent developments

Concerning the malignant lymphomas, a partial significant progress occured in recent years. So, basic knowledge has deepened, anew-transatlantic classification has been introduced and different therapeutic concepts in aggressive lymphoma can now be evaluated. Breakthroughs in the treatment of clinically indolent cases are expected, while the optimal procedure in regard to MALT-lymphomas is still contentious. The long-standing stagnation of both the treatment of recurring illness and the avoidance of treatment related side effects was not surmountable. With respect to this situation, it is reasonable to summarize present data. This paper gives an overall perspective.